XOMA (NASDAQ:XOMA) Shares Pass Above Two Hundred Day Moving Average of $25.18

XOMA Co. (NASDAQ:XOMA) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $25.18 and traded as high as $29.65. XOMA shares last traded at $29.14, with a volume of 30,870 shares trading hands.

Analyst Ratings Changes

XOMA has been the topic of a number of recent research reports. HC Wainwright lifted their price target on shares of XOMA from $74.00 to $117.00 and gave the stock a “buy” rating in a research note on Thursday, August 15th. Leerink Partners assumed coverage on shares of XOMA in a research report on Monday, April 29th. They set an “outperform” rating and a $40.00 target price on the stock. Leerink Partnrs reissued an “outperform” rating on shares of XOMA in a research report on Monday, April 29th. Finally, StockNews.com raised XOMA from a “sell” rating to a “hold” rating in a report on Wednesday, August 14th.

XOMA Stock Performance

The company has a quick ratio of 8.71, a current ratio of 8.71 and a debt-to-equity ratio of 1.15. The stock has a fifty day simple moving average of $26.09 and a 200-day simple moving average of $25.18. The company has a market capitalization of $340.94 million, a P/E ratio of -7.43 and a beta of 0.93.

Hedge Funds Weigh In On XOMA

Several institutional investors have recently added to or reduced their stakes in XOMA. BNP Paribas Financial Markets grew its stake in XOMA by 55.6% during the first quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company’s stock worth $85,000 after buying an additional 1,266 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new position in shares of XOMA in the 1st quarter worth approximately $212,000. Rhumbline Advisers grew its position in XOMA by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after acquiring an additional 1,334 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in XOMA by 3.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares in the last quarter. 95.92% of the stock is owned by institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.